# 502702905 03/03/2014

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT2749511

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
JANSSEN PHARMACEUTICALS, INC.	07/14/2009

#### RECEIVING PARTY DATA

Name:	CELLZOME LIMITED	
Street Address:	980 GREAT WEST ROAD	
City:	BRENTFORD, MIDDLESEX	
State/Country:	UNITED KINGDOM	
Postal Code:	TW8 9GS	

## PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	13382659

## CORRESPONDENCE DATA

Fax Number: (215)568-3439 Phone: 215568-3100

Email: assignments@woodcock.com

Correspondence will be sent via US Mail when the email attempt is unsuccessful.

Correspondent Name: BAKER & HOSTETLER LLP
Address Line 1: CIRA CENTRE - 12TH FLOOR

Address Line 2: 2929 ARCH STREET

Address Line 4: PHILADELPHIA, PENNSYLVANIA 19104

ATTORNEY DOCKET NUMBER:	100892.000213 / PRD3090US
NAME OF SUBMITTER:	JANIS CALVO
Signature:	/Janis Calvo/
Date:	03/03/2014

Total Attachments: 1

source=CELLZOME ASSIGNMENT#page1.tif

PATENT REEL: 032333 FRAME: 0624

## General Assignment

WHEREAS, Janssen Pharmaceuticals, Inc. (formerly known as Ortho-McNeil-Janssen Pharmaceuticals, Inc.), having its place of business at 1125 Trenton-Harbourton Road, Titusville NJ 08560, USA (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

for which on the 13<sup>th</sup> day of July 2010, International Application PCT/EP2010/060083 was filed at the European Patent Office, claiming priority of European Patent Application no. 09165585.2 which was filed on the 15<sup>th</sup> day of July 2009 at the European Patent Office and of European Patent Application no. 10164625.5 which was filed on the 01<sup>st</sup> day of June 2010 at the European Patent Office.

WHEREAS, Cellzome Limited, having its place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom (hereinafter referred to as "Assignee") is desirous of acquiring 50% of the Assignors' entire right, title and interest therein.

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee 50% of its entire right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

The Assignor agrees that this general assignment is effective from the 14th of July 2009.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Pharmaceuticals/Inc.

Luc Quaghebeur Assistant Secretary

Janssen Pharmaceuticals, Inc.

For Cellzome Limited

Helen K Quillin

Attorney and Authorised Official

Cellzome Limited

PATENT REEL: 032333 FRAME: 0625